Julia Rotow, MD / Javier Cortés, MD - HER3-Targeted Therapies: How Might These Benefit Our Patients‪?‬ PeerVoice Clinical Pharmacology Audio

Visit https://www.peervoice.com/SZV860 to view the entire programme with slides. After completing “Julia Rotow, MD / Javier Cortés, MD - HER3-Targeted Therapies: How Might These Benefit Our Patients?”, participants will be able to: Recall the molecular and pathological mechanisms of HER3 that make it a promising therapeutic target in non-small cell lung cancer (NSCLC) and breast cancer; and Assess the clinical relevance of safety and efficacy data from randomised clinical trials evaluating HER3-targeted agents.